Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial.
0/5 보강
APA
Yamada Y (2026). Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial.. Translational andrology and urology, 15(1), 7. https://doi.org/10.21037/tau-2025-703
MLA
Yamada Y. "Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial.." Translational andrology and urology, vol. 15, no. 1, 2026, pp. 7.
PMID
41658468
같은 제1저자의 인용 많은 논문 (5)
- Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy.
- PEComas of the colon and rectum: a case report of a 15-year-old girl and a review of the pertinent literature.
- The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer.
- Refractory Clinical Course of Acute Myeloid Leukemia With t(8; 10; 21)(q22; q22; q22.1): A Case Report and Literature Review of This Variant Form.
- Pre-treatment C-reactive protein level is a prognostic marker of patients treated with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.